Single-cell genetics identifies cell type-specific causal mechanisms in complex traits and diseases

Albert Henry[1,2,3,4,*], Anne Senabouth[1,2,*], Rika Tyebally[1,2], Blake Bowen[1,2,3], Peter C. Allen[1,2], Eleanor Spenceley[1,2,3], Eszter Sagi-Zsigmond[1], Anna S.E. Cuomo[1,2,3,5,6], Jianan Fan[1,2], Hao Lawrence Huang[1,2,3], Hope A. Tanudisastro[2,5,6,7], Angli Xue[1,2,3], Katrina M. de Lange[1,2,3], Gemma A. Figtree[8,9], Alex W. Hewitt[10,11,12], Daniel G. MacArthur[2,5,6], Joseph E. Powell[1,2,3,**]

[1]Translational Genomics Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.

[2]Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia

[3]UNSW Cellular Genomics Futures Institute, University of New South Wales, Sydney, NSW, Australia

[4]Institute of Cardiovascular Science, University College London, London, UK

[5]Centre for Population Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia

[6]Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia

[7]Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

[8]Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia

[9]Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia

[10]Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia

[11]Department of Ophthalmology, Royal Hobart Hospital, Hobart, TAS, Australia

[12]Centre for Eye Research Australia, University of Melbourne, East Melbourne, VIC, Australia

* equal contribution

** Correspondence: j.powell@garvan.org.au

Abstract

Genome-wide association studies (GWAS) have been instrumental in uncovering the genetic basis of complex traits. When integrated with expression quantitative trait loci (eQTL) mapping, they can elucidate how risk loci influence traits through gene regulatory mechanisms. Recent single-cell eQTL (sc-eQTL) studies suggest that genetic effects on gene expression are often cell type- and subtype-specific, but such datasets have so far been underpowered for causal inference. Here, we leverage results from sc-eQTL mapping in the TenK10K project, comprising 154,932 common variant sc-eQTL across 28 immune cell types derived from matched whole-genome sequencing (WGS) and single-cell RNA-sequencing (scRNA-seq) of over 5 million peripheral blood mononuclear cells (PBMCs) from 1,925 individuals. We present a catalogue of cell type-specific causal effects of gene expression on 53 diseases (spanning 58,058 causal associations across 8,672 genes and 28 cell types), and 31 biomarker traits (spanning 674,764 causal associations across 16,078 genes and 28 cell types). By quantifying polygenic enrichment at both the single-cell and cell-type levels, we identify distinct immune cell contributions to both immune-related and systemic conditions. We demonstrate differential polygenic enrichment of Crohn's disease and COVID-19 amongst dendritic cell subtypes, and high activity of B cell interferon II response in SLE. Integration with clinical drug development data reveals that therapeutic compounds targeting gene-trait associations identified in this study are three times more likely to have secured regulatory approval. Using Crohn's disease as a motivating example, we demonstrate how population-based sc-eQTL data can pinpoint risk loci, effector genes and cell types, complementing findings from disease-focused tissue samples. Our findings provide a foundational resource for understanding the cell type-specific genetic architecture of disease and for guiding therapeutic discovery.

Introduction

Genome-wide association studies (GWAS) have identified thousands of loci associated with complex traits and diseases; yet, the majority of these signals reside in non-coding regions, complicating efforts to pinpoint causal genes and mechanisms[1]. Many non-coding variants act through gene regulatory mechanisms[2], influencing gene expression in a manner that is often highly cell type-specific[3–5]. This presents a significant challenge in pinpointing molecular mechanisms of diseases in heterogeneous tissues, where regulatory effects are often obscured in bulk transcriptomic analyses.

Single-cell genomics has transformed our understanding of gene regulation, revealing that the effects of genetic variation on gene expression can vary across different cell types and states. Consequently, single-cell expression quantitative trait loci (sc-eQTL) data have emerged as a promising avenue for identifying the cellular contexts in which genetic variants exert their effects. However, existing sc-eQTL studies have been underpowered[5], limiting their utility in causal inference of disease mechanisms.

Recent efforts to integrate GWAS data with single-cell transcriptomic atlases have highlighted disease-relevant cell types and programs. These approaches can be broadly categorised into two main types: those based solely on cell atlases[6] without consideration of genotypes, and those that incorporate genetic effects on single-cell molecular phenotypes[3,7–9]. Methods such as cell type enrichment scoring and topic modelling of gene expression patterns have linked regulatory programs to complex traits[10,11]. However, such approaches primarily establish correlation and do not directly assess whether genetically driven changes in gene expression causally contribute to disease risk. This distinction is particularly important in the immune system and complex tissues, where co-expression and linkage disequilibrium can confound signal interpretation.

In contrast, causal inference frameworks such as Mendelian randomisation (MR) test whether genetically-predicted gene expression has a directional effect on disease[12–14]. Owing to random allocation of genetic variants at conception and the fact that they remain fixed over the life course, sc-eQTL variants can be used as genetic instruments to predict gene expression. Under specific assumptions[12–14], these genetically-predicted gene expressions can be integrated with disease-specific genetic association estimates from GWAS through MR analysis, providing a platform to distinguish correlation from causation at cell type-specific and disease-specific resolution.

Here, we present a comprehensive framework for inferring causal gene–trait relationships by integrating sc-eQTL data from Phase 1 of the TenK10K project, which comprises matched whole-genome sequencing and single-cell RNA sequencing of over 5 million peripheral blood mononuclear cells across 28 immune cell types in 1,925 individuals. We applied MR using multiple sc-eQTL instruments to test the causal effects of 17,446 genes on 69 complex diseases and 31 biomarker traits. This revealed gene–trait associations that are

highly cell type-specific, including many not detectable by comparable methods using GWAS data only and bulk-tissue MR with whole blood eQTL instruments.

We further quantified polygenic enrichment across individual cells and cell types, identifying both immune-related and systemic disease associations, including cancer, neuropsychiatric, and cardiometabolic traits, with distinct cellular origins. We intersected these results with deep learning-derived cell function scores to prioritise biological processes involved in the pathogenesis of systemic lupus erythematosus (SLE). To explore the translational relevance of these findings, we intersected our causal gene–trait map with clinical drug development data from the Open Targets Platform[5]. We found that drugs whose targets matched our predicted gene–trait pairs were three times more likely to achieve regulatory approval.

Finally, we demonstrate how these findings can be used to identify effector genes and new therapeutic targets for Crohn's disease through triangulation of evidence from our study and an independent study measuring changes in gene expression using single-cell dataset from patients. Together, this study provides a population-scale, cell type-resolved map of causal effects of gene expression on complex traits, offering a valuable resource for advancing mechanistic understanding and therapeutic development.

Results

Landscape of causal associations between gene expression and complex traits across immune cells

We recently profiled the transcriptomes of 5,920,025 peripheral blood mononuclear cells (PBMCs) collected from 1,925 donors as a part of the first phase of the TenK10K project[15]. These cells encompassed 28 immune cell types and integration with matching whole genome sequencing (WGS) data revealed 154,932 common variant sc-eQTLs (minor allele frequency > 1%) for 17,674 eGenes (genes with at least one *cis*-eQTL). The majority of eGenes exhibited cell-type restricted effects, with only half of all identified eGenes being shared amongst at most a quarter of the cell types[15], highlighting the importance of cell-resolved approaches for linking regulatory variants to complex trait risk.

To quantify causal relationships between cell type-specific gene expression and complex traits, we applied a multi-instrument summary data-based Mendelian randomisation (MR) framework using sc-eQTL as proxies for gene expression[14] at the cell type level (**Figure 1a**). We compared this to an alternative method that prioritises trait-associated genes directly from GWAS data (hereafter referred to as GWAS genes) using gene-level aggregation of genetic association estimates with MAGMA[16]. Analysis was restricted to genes expressed in at least one cell type and with at least one significant *cis*-eQTL, for which corresponding variants were available across harmonised GWAS summary statistics (**Methods**).

We tested 17,444 eGenes (including 12,873 protein-coding genes) across 28 immune cell types, with a median of 5,947   eGenes (4,693 protein-coding) per cell type (**Figure 1b**, **Supplementary Table 1**). For each gene-cell type pair, we estimated causal effects on 69 complex diseases and 31 biomarker traits spanning 10 categories (**Figure 1c**, **Supplementary Table 2**). This yielded 15,101,807 gene–cell type–trait combinations, of which 732,822, (4.9%) passed the discovery threshold ($Q_{MR} < 0.05$ and heterogeneity in dependent instrument / HEIDI test $P_{HEIDI} > 0.01$). Across disease traits, we identified 58,058 unique causal associations from combinations of 53 diseases, 28 cell types, and 8,672 genes (6,801 protein-coding). The median number of unique genes with causal associations was 1,579 per cell type, 48 per disease, and 9 per cell type-disease pair (**Supplementary Figure 1, Supplementary Table 3**). Across biomarker traits, 674,764 causal associations were identified from combinations of 16,078 unique genes (12,076 protein-coding), 31 traits, and 28 cell types. The median number of unique genes with causal associations was 4,883 per cell type, 6,077 per trait, and 788 per cell type-trait pair (**Supplementary Figure 2, Supplementary Table 3**). Across the 28 immune cell types, the number of significant MR gene-trait associations ranged from 2,088 for ILC cells to 50,692 for NK cells (median = 28,954). This count scaled linearly with the total number of MR tests performed per cell type (**Supplementary Figure 3**), with a consistent proportion of significant results across cell types (mean = 5.0%, SD = 0.3%). These findings establish a high-resolution, cell-type-specific map of gene–trait relationships across the circulating immune system.

Trait-level insights from cell type-specific causal gene mapping

We identified 188,634 unique gene-trait associations in at least one cell type for 53 diseases and 31 biomarker traits. The number of significant MR-based gene associations per trait was strongly correlated with the number of GWAS-prioritised genes identified using MAGMA (Pearson's $r = 0.97$), with an approximately exponential relationship between the two (**Supplementary Figure 4**). Of the 188,634 unique gene-trait associations identified by single-cell MR, 65,355 (35%) were not identified by using MAGMA with GWAS data only, with a median of 38 (18%) per trait (**Supplementary Figure 5**, **Supplementary Table 4**). Importantly, MR-identified associations not detected by GWAS were more likely to be restricted to a small number of cell types (**Figure 2a**). A similar pattern was observed in comparison with bulk-tissue MR using genetic instruments derived from whole blood eQTL from eQTLgen[17], wherein 114,631 (61%) gene-trait associations were not identified (median = 178 / 65% per trait) (**Supplementary Figure 6**, **Supplementary Table 4**). These comparisons underscore the added value of eQTL mapping at single-cell resolution for identifying effector genes with cell type-specific roles in complex traits.

Figure 1 | Study design and causal inference using single-cell eQTLs.
a) Overview of study design. We integrated single-cell eQTL data from 5 million peripheral blood mononuclear cells (PBMCs) (covering 28 immune cell types) profiled in the TenK10K Phase 1 cohort (1,925 donors) with GWAS summary statistics for 100 complex traits (69 diseases and 31 biomarkers) using a multi-instrument Mendelian randomisation (MR) framework. **b**) Number of eGenes (genes with at least one significant cis-eQTL) included in the MR analysis per cell type, stratified by gene type (protein-coding vs non-coding). Median of 5,947 eGenes per cell type. **c**) Number of trait-associated genes identified using GWAS summary statistics alone via MAGMA (FDR < 5%) across the 100 traits. Each point represents a trait; the point size reflects the effective sample size of the GWAS, and the colour indicates the trait category (e.g., immune, cancer, cardiometabolic).

In addition to identifying causal genes, MR also helps in resolving the causal effect direction on trait outcomes, providing critical information to distinguish between targeting upregulation and downregulation of gene expression in drug design. Across all significant MR associations in our study, the direction of effect was evenly split between positive (n=365,985) and negative (n=366,837), indicating a balanced contribution of activating and repressing regulatory effects on trait outcomes (**Figure 2b**). This symmetry was consistent across both phenotype categories and cell types, implicating that disease-relevant gene networks involve a balance of activation and inhibition.

Across trait categories, traits closely related to peripheral blood composition yielded the highest number of associations, including 163,383 unique gene-trait associations across 26 blood biomarker traits. Substantial numbers of associations were also detected for cancer-related traits (5,375 associations across 20 traits), and immune-mediated diseases (2,943 associations across nine traits) (**Figure 2b**). Polygenic traits with large GWAS sample sizes also showed strong MR signals, including type 2 diabetes mellitus (5,608 associations), estimated heel bone mineral density (7,982 associations), and schizophrenia (1,033 associations) (**Figure 2c**, **Supplementary Table 3**). These associations were spread across immune cell types, but correlated with the number of eGenes identified from the sc-eQTL mapping (**Supplementary Figures 1-2**). Similar patterns of the relative number of MR genes across cell types were observed amongst top-associated traits in each category (**Figure 3c**). These findings imply that context-specific gene expression in PBMCs may play a causal role in complex traits beyond immune-related traits, or that these cells share a similar genetic regulation of gene expression with trait-relevant cell types in other tissues.

Figure 2 | Cell type-specific causal gene-trait associations across complex traits.
a) Distribution of gene-trait associations with MR evidence by the number of cell types in which the association is detected. Left y-axis: total number of gene–trait pairs (bars). Colours distinguish associations identified by MR only versus those also supported by GWAS ($Q_{MAGMA} < 0.05$). Right y-

axis: proportion of MR-significant associations also supported by GWAS (red line and points). **b)** Number of significant gene-trait pairs identified by Mendelian randomisation (MR) across trait categories. Associations are defined as $Q_{MR} < 0.05$, $P_{HEIDI} \geq 0.01$. Bar color indicates the direction of association (positive or negative) with an increased gene expression. **c)** Same as panel b, but for comparison against results from MR using eQTL derived from bulk whole blood expression data from eQTLgen consortium. **d)** Bar charts showing number of genes with MR associations (MR genes) by cell types across selected 48 traits (out of 100 tested). The traits are displayed in subpanels within a grid (8 rows, 6 columns) and ordered row-wise in descending order by number of unique MR genes as displayed on the top-right corner of each trait subpanel, with a background coloured by trait category. Only traits with the top 10 highest number of unique MR genes per category and with 10 or more unique MR genes are displayed. The full results are presented in **Supplementary Figures 8-9**.

Polygenic enrichment reveals trait-relevant immune cell types and gene programs

To identify the immune cells involved in the genetic architecture of complex traits, we performed a polygenic enrichment analysis using the single-cell Disease Relevance Score (scDRS) framework[10]. We analysed 100 traits across the 28 immune cell types profiled in Phase 1 of the TenK10K study by computing cell-level scDRS score at cell-level, and statistics for polygenic enrichment at both cell-level and cell type-level using the default scDRS permutation scheme. To control for differences in cell abundance, we randomly sampled up to 10,000 cells per cell type, yielding a dataset of 229,239 cells.

We quantified the proportion of phenotype-enriched cells (cell-level $P_{scDRS} < 0.05$) within phenotype-enriched cell types (cell-type-level $P_{scDRS} < 0.05$) for each trait (**Figure 3a, Supplementary Table 5**). All 28 cell types showed enrichment for at least one phenotype (mean = 14.6 traits per cell type), with cDC1 (39 traits), cDC2 (37 traits), and CD4 proliferating T cells (31 traits) showing the strongest polygenic enrichment (**Supplementary Figure 7**). In total, 95 of 100 traits were enriched in at least one cell type (mean = 4.3, max = 10). Immune-mediated diseases showed the highest number of enriched cell types, as expected; for example, psoriasis was enriched in 10 cell types. We also observed enrichment of non-immune polygenic traits, including estimated heel bone mineral density (9 cell types), Alzheimer's disease (7), and schizophrenia (7).

At single-cell resolution, the proportion of enriched cells per trait ranged from 8% and 79% (median = 18.7%) (**Figure 3a**). The strongest enrichment was observed for a negative antibody response to the first dose of the COVID-19 vaccine (no antibody detected post-vaccination), where 79% of cells from enriched cell types were significantly associated with the trait, but predominantly enriched in antibody-producing B cells. As expected, monocyte count traits were enriched in CD14+ and CD16+ monocytes, and lymphocyte count traits in T cell subsets. Notable examples also included enrichment of systemic lupus erythematosus in B cells; lung and breast cancers in proliferating cells, and coronary artery disease and Alzheimer's disease in monocytes (**Figure 3a**). These findings suggest that complex trait-associated variants, including those not traditionally linked to immune function, can affect gene expression patterns across diverse immune cell types.

Using Crohn's disease as a case study, we identified 12,199 out of 56,920 sampled cells
(21%) as enriched for polygenic signals across eight cell types (**Figure 3b**). The most enriched
cell types, ranked by Z_{scDRS} statistics, were cDC2, MAIT, cDC1, NK CD56[bright], ASDC, CD14
Monocytes, and CD4 TEM ILC cells. Enrichment proportions ranged from 9.2% in CD4+
TEM to 54.3% in cDC2 (**Figure 3c**). Dendritic cells, particularly cDC2 and cDC1, showed
the strongest enrichment. These results are consistent with prior reports of dendritic cell
infiltration and activation in Crohn's-affected intestinal tissue[18], including overexpression of
chemokine receptors involved in T cell recruitment. We also observed enrichment in ASDCs,
a less-characterised dendritic subset with unclear roles in autoimmunity[19]. In contrast,
plasmacytoid dendritic cells (pDCs) did not show enrichment for Crohn's disease but were the
only dendritic subtype enriched for COVID-19 hospitalisation (**Figure 3d**), consistent with
their established role in antiviral immunity and type I interferon production[20].

The polygenic enrichment analysis also facilitates the identification of trait-related cell
functions through integration with scDeepID, an in-house deep learning method to quantify
cell function as cell states at single-cell resolution (see **Methods**). Using B cells in Systemic
Lupus Erythematosus (SLE) as an example, we leveraged scDeepID to compute 400
representative cell function scores in 539,820 B cells (including B naive, B intermediate, and
B memory cell types) identified in the TenK10K phase 1 study. We extracted cell function
scores for the 30,000 sampled B cells used in the scDRS analysis, and compared the average
cell function scores between 17,264 SLE-enriched cells (cell-level $P_{scDRS\text{-}SLE} < 0.05$) and
12,736 non-SLE-enriched cells using a one-sided T-test. We identified 202 cell functions with
a higher average score in the SLE-enriched cells compared to non-SLE-enriched cells at $Q <$
0.05 (**Supplementary Figure 8, Supplementary Table 6**). The cell functions with the highest
mean score difference based on Q value include cellular response to type II interferon, positive
regulation of inflammatory response, tumour necrosis factor-mediated signalling pathway,
biological process involved in interaction with host, and leukocyte-mediated cytotoxicity
(**Supplementary Figure 9a-b**). The scores of these five cell functions also showed a trend of
linear increase across deciles of scDRS$_{SLE}$ (**Supplementary Figure 9c**), implicating
involvement of these pathways and their gene members in the pathogenesis of SLE.

To assess the robustness of our sampling strategy, which oversampled rare cell types,
we conducted a sensitivity analysis using proportional sampling (10% of cells per cell type)
(**Methods**). Both the distribution of cell-level scDRS scores and the proportion of phenotype-
enriched cells remained consistent (**Supplementary Figures 10-11**), confirming that
enrichment patterns were not artefacts of oversampling.

Figure 3 | Polygenic enrichment of complex traits across immune cell types.
a) Average proportion of phenotype-enriched cells across 100 complex traits, stratified by immune cell types. Enrichment was calculated using the single-cell disease relevance score (scDRS); cells were considered enriched if their scDRS $P < 0.05$ and belonged to cell types with significant trait enrichments (cell-type-level $P_{scDRS} < 0.05$). **b.** UMAP embedding of 229,236 sampled peripheral immune cells, coloured by scDRS score for Crohn's disease. Only cells from the seven cell types with significant

enrichment (cell-type level $P_{\text{scDRS}} < 0.05$) are coloured; all other cells are shown in grey. **c.** Distribution of scDRS scores for Crohn's disease across the 28 immune cell types. Cell types are ordered by scDRS Z-score, and those with significant enrichment ($P_{\text{scDRS}} < 0.05$) are highlighted in red. **d.** Mean scDRS score across deciles of cell-level scDRS for COVID-19 and Crohn's disease across four dendritic cell subtypes (cell type-level $P_{\text{scDRS}} < 0.05$). Cell types without evidence of enrichment ($P_{\text{scDRS}} \geq 0.05$) are faded out, demonstrating contrasting enrichment patterns across diseases and dendritic cell subsets.

Single-cell MR supports drug target discovery and clinical translation

Recent studies have shown that drugs supported by human genetic evidence are more likely to advance through the drug development pipeline and gain regulatory approval[21,22]. Single-cell transcriptomics can further refine target validation by resolving cell type specificity within disease-relevant contexts[23]. Since most drug targets are proteins encoded by genes, the cell-resolved causal associations uncovered by our sc-eQTL MR framework may offer novel insights into tractable therapeutic mechanisms.

To evaluate this, we cross-referenced our MR results with curated drug development data from the Open Targets Platform[24] (version 25.06). First, we focused on 12,873 protein-coding genes tested in the MR analysis and 57 diseases with at least one matching indication available in the Open Targets, yielding 733,761 possible gene-indication pairs, hereafter the target-indication universe. Of these, 13,196 pairs (1.8%) were supported by MR evidence in at least one cell type (**Methods**).

According to drug development activity data (from ChEMBL[25]), 6,712 target–indication pairs (involving 853 targets and 56 indications) have been investigated in clinical trials. Among these, 174 pairs (2.6%) were supported by our MR analysis. Notably, 473 of the 853 clinically tested targets (55%) had MR support for at least one indication in our dataset, including 151 targets that have received regulatory approval (**Figure 4**, **Supplementary Table 7**). MR-supported target–indication pairs were more likely to be observed across all stages of clinical development (**Figure 4b**, **Supplementary Table 8**), with approved indications showing the highest enrichment. Overall, MR-supported pairs were 3.3 times more likely to reach regulatory approval than unsupported pairs (odds ratio = 3.3; lower 95% CI: 2.41; $P = 7.1 \times 10^{-9}$, one-sided Fisher's exact test).

To further validate this association, we compared Open Targets evidence scores for drug–indication pairs with and without MR support. The Open Targets score is a normalized metric (0–1) derived from diverse evidence sources, including genetic associations, somatic mutations, expression data, animal models, and literature mining (**Methods**). Pairs supported by MR showed significantly higher evidence scores overall (mean = 0.37 vs. 0.26; $P = 2.3 \times 10^{-9}$; **Figure 4c, Supplementary Table 9**). Stratifying by evidence type, we found stronger support for MR-backed pairs in both genetic evidence (mean = 0.52 vs. 0.42; $P = 7.7 \times 10^{-3}$) and non-genetic sources (mean = 0.38 vs. 0.33; $P = 6.3 \times 10^{-3}$), with a more pronounced effect in the genetic category.

Next, we assessed the concordance between the direction of MR effect and the mechanism of action (MoA) of drugs at the most advanced clinical development stage for each target–indication pair (**Figure 4d, Supplementary Table 10**). On average, MR-supported pairs more often showed concordant MoA, for instance, risk-increasing (positive effect) MR results aligning with inhibitors, or protective (negative effect) results aligning with agonists. This pattern was especially pronounced for drugs in Phase III trials or with regulatory approval. Moreover, MR-supported targets in later development stages were associated with stronger evidence of causal effect (**Figure 4e, Supplementary Table 10**).

Finally, we examined selected examples from the 174 MR-supported target–indication pairs (covering 131 genes and 25 diseases) in more detail (**Figure 4f, Supplementary Figure 12, Supplementary Table 10**). These included several known immune targets of approved therapies: JAK2 and TNF for Crohn's disease, IL6R for rheumatoid arthritis, and IL23A and IL17RA for psoriasis. Importantly, our analysis also identified high-confidence targets in diseases not classically associated with immune dysfunction, including APP (amyloid precursor protein) for Alzheimer's disease and GLP1R (glucagon-like peptide-1 receptor) for type 2 diabetes.

APP encodes a precursor to Amyloid-β peptides, whose aggregation forms amyloid plaques linked to synaptic dysfunction and cognitive decline in Alzheimer's disease[26]. GLP-1R, a receptor primarily expressed in the pancreas and brain, modulates insulin secretion and glucose metabolism through binding to GLP-1 proteins[27]. Initially developed for diabetes, GLP-1R agonists (e.g., semaglutide) have recently shown efficacy in reducing cardiovascular risk[28] and promoting weight loss[29] in individuals without diabetes. These examples highlight how cell type-specific MR results can identify therapeutically actionable targets across complex diseases including cases where the encoding genes are primarily expressed in other tissues, potentially due to shared genetic regulation.

Figure 4 | Single-cell MR supports drug target validation and clinical development success.
a) Number of protein-coding gene targets with MR support ($Q_{MR} < 0.05$; $P_{HEIDI} \geq 0.01$) across clinical development stages, as defined by target–indication pairs in the Open Targets Platform (OTP). Bars are grouped by the maximum development phase for each pair. **b)** Enrichment of MR-supported target–indication pairs among clinically investigated indications. Odds ratios and lower 95% confidence intervals are shown for pairs with versus without MR support, stratified by maximum clinical development phase. Right-

side annotations indicate counts of MR-supported target–indication pairs over the total number of clinically investigated pairs per phase. **c)** Distribution of OTP evidence scores for target–indication pairs with and without MR support. Scores are shown for all evidence sources (overall), as well as genetic and non-genetic sources separately. **d)** Number of MR-supported target–indication pairs, stratified by predicted direction of MR effect (positive or negative) and mechanism of action (MoA) of drugs with the highest OTP evidence score. Data are grouped by maximum clinical development stage. **e)** Strength of MR evidence ($-\log_{10} P_{MR}$) for target–indication pairs across clinical development stages. **f)** MR-supported targets for five selected diseases. Each bar represents a target–indication pair, ordered by OTP overall association score and coloured by maximum clinical development phase. The top five targets by OTP score are labelled.

Single-cell genetics reveals causal cell-type-specific mechanisms in Crohn's disease

To illustrate the added resolution of single-cell MR, we present a focused case study of Crohn's disease—a chronic inflammatory disorder of the gastrointestinal tract characterised by disrupted epithelial integrity, microbial dysbiosis, and dysregulated immune signalling[30,31]. Genetic studies have implicated immune-related genes and pathways involved in autophagy, cytokine signalling, and endoplasmic reticulum stress in disease pathogenesis[32].

Using our single-cell MR framework, we identified 1,791 gene-cell type pairs and 510 unique genes (407 protein coding) with evidence of a causal relationship with Crohn's disease across 28 immune cell types (**Supplementary Figure 13**). Of these, 88 were not detected using MAGMA-based gene prioritisation from GWAS data alone, and 339 were not identified using bulk whole blood-based MR (**Supplementary Figure 14**). A total of 209 genes (163 protein-coding) exhibited cell-type-specific MR associations, defined as significant in only one cell type. Notably, 146 (71%) of these were not detected in bulk-tissue whole blood MR, highlighting the unique resolution provided by single-cell approaches (**Supplementary Table 11**). Of the 1,791 gene-cell type pairs with MR evidence, between 66 to 1,076 pairs were also causally associated with other immune diseases (in descending order of shared signals: inflammatory bowel disease, ulcerative colitis, psoriasis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and eczema), potentially revealing shared causal molecular pathways. Of the 1,791 gene-cell type pairs with MR evidence, 232 (13%) demonstrate discordant directions of effect between diseases, highlighting disease context-dependent causal effects (**Supplementary Table 12**).

As a proof-of-principle, we recovered known therapeutic targets for Crohn's disease, including *TNF*, *IL23R*, and canonical risk genes such as *ATG16L*, *NOD2*, and *IRGM* (**Supplementary Table 13**, **Figure 5a**). Interestingly, we observed divergent directions of causal effect for 61 genes (20%), where the same gene exhibited opposing MR directions in different cell types. For example, *NCF4* (which encodes a component of an enzyme complex in phagocytes), showed a positive effect in B memory cells but a negative effect in B naive cells (**Figure 5b**), suggesting context-specific regulatory roles. The negative effect of *NCF4* in B naive cells is also observed in eczema. Interestingly, while the positive effect of *NCF4* in B memory cells is also observed in psoriasis, it has a negative effect in multiple sclerosis (**Supplementary Table 12**).

To validate the biological relevance of our findings, we compared MR-identified genes with differentially expressed genes from single-cell RNA-seq of colon biopsies from 46 patients with Crohn's disease and 25 healthy controls[33]. While some intestinal immune cells are tissue-resident, many cell type lineages, such as B cells, T cells, dendritic cells, and NK cells, are shared between peripheral and tissue compartments. We harmonised cells between datasets by major cell types, excluding tissue-specific subsets such as macrophages (**Supplementary Figure 15**), and examined the consistency of MR directionality with differential expression.

We reasoned that genes with a positive MR effect (*i.e.*, risk-increasing) would be upregulated in disease tissue, whereas those with a negative MR effect (protective) would be downregulated. We identified a total of 116 genes with matched major cell types. Of these, 62 genes had concordant direction of effect between MR and DEG, 47 with discordant effects and 7 with both concordant and discordant effects, depending on concordance between and within major cell types (**Supplementary Table 14, Supplementary Figure 16**). We highlight *ZBTB38* as an interesting example with convergent evidence: it showed a positive MR effect and was upregulated in B cells, CD4+ T cells, and CD8+ T cells from Crohn's disease colon samples (**Figure 5c**). Conversely, *TNFRSF18* (a known immune modulator) showed a protective MR effect but was also upregulated in CD4+ T cells from Crohn's disease colon, suggesting potential compensatory mechanisms due to reverse causation (**Supplementary Table 14, Supplementary Figure 16**).

Together, these results demonstrate how single-cell MR can identify both established and uncharacterised causal genes with cell-type-specific effects, refine interpretation of differential expression studies, and inform mechanistic hypotheses for complex disease biology.

Figure 5 | Cell-type-specific causal and transcriptional signatures in Crohn's disease.
a) Selected MR-significant genes in Crohn's disease, shown as $-\log_{10} P_{MR}$ multiplied by direction of
MR estimate of the lead instrument. Only protein coding genes are shown. A positive direction denotes
increased disease risk with increased expression, and negative direction denotes reduced disease risk

for increased expression. Gene categories include canonical risk genes, approved drug targets and their
pathways (combined), and differentially expressed genes in matched major cell types of colon immune
cells of Crohn's disease patients (DEGs) with concordant direction of effect (See **Methods** and
Supplementary Table 12). Genes denoted with an asterisk are both canonical or drug target genes and
DEGs. DEGs were identified from colon biopsy scRNA-seq data (Kong et al., 2023)[33] by matching
genes and major immune cell types with MR results. Empty grids indicate the gene was not an eGene
in that cell type and was therefore not tested. Black outlines denote MR associations ($Q_{MR} < 0.05$; P_{HEIDI}
> 0.01). **b)** Causal effect plots showing GWAS effect sizes (y-axis) against cell type-specific sc-eQTL
SNP effect sizes (x-axis), paired with locus zoom plots for selected genes. Data points in both plots
represent common genetic variants in the *cis*-region of the gene that are available in both GWAS and
sc-eQTL datasets. Variants used as instruments for gene expression in the MR analysis are highlighted
in red, and lead instruments (lowest sc-eQTL P) are circled in purple. The slope in the effect plot
corresponds to the point estimate of the MR effect size (coefficient) of the lead instrument. Row 1 and
2, respectively: positive causal effect of *NCF4* in B memory cells and negative causal effect of *NCF4*
in B naive cells; Row 3: positive causal effect of *ZBTB38* in CD4+ naive cells. **c)** Colon immune cells
from Kong et al., 2023, colour-coded by major cell type annotations derived by mapping major cell
types with the TenK10K study (see **Methods, Supplementary Table 16**). Unmatched major cell types
are excluded (original annotations of the full datasets are presented in **Supplementary Figure 16**). **d)**
Expression of *NCF4* and *ZBTB38*, which both have causal effects on Crohn's disease in circulating
immune cells and differential expression in colon immune cells. Colon immune cells are projected on
the UMAP coordinates from panel c, stratified by disease and inflammation status.
448

Discussion

By integrating population-scale sc-eQTL data from 1,925 individuals in the TenK10K
cohort with genome-wide association study (GWAS) results, we generated a comprehensive
map of cell type-specific causal gene–trait relationships across 28 peripheral immune cell types
and 100 complex traits. Using a multi-instrument Mendelian randomisation (MR) framework,
we identified over 8,000 genes with evidence of causal association with at least one disease,
and over 16,000 with at least one biomarker. In total, this resulted in 190,343 unique gene–trait
associations, spanning 739,538 gene–trait–cell type combinations. These findings align with
the postulated genetic architecture of complex traits, where trait-associated variants are
numerous, context-specific, and distributed across diverse regulatory programs[34,35]. Given that
genes and variants exhibit pleiotropic effects[36], and that diseases may share causal molecular
aetiology[37], this cell type-resolved causal association map provides a platform for prioritising
fundamental mechanisms underlying complex traits.

Approximately one-third (34%) of gene–trait associations identified through MR were
not recovered using conventional gene-based GWAS approaches (*e.g.*, MAGMA), and the
majority of these were specific to a single or small number of cell types. This underscores the
value of cell-resolved sc-eQTL data for uncovering regulatory effects that are masked in bulk
tissue analyses. Notably, we found that 61% of the gene-trait associations identified in our
study were undetectable in a comparable MR analysis using genetic instruments derived from
bulk-tissue eQTL mapping of whole blood sample from eQTLgen[17], despite having 16 times
larger sample size for eQTL discovery. These findings affirm the hypothesis that cell-specific
genetic regulations are undetectable in aggregated datasets, further reinforcing the utility of
single-cell resolved eQTL mapping.

While our analysis focused on PBMCs, we identified causal associations not only for immune-related diseases and blood traits, but also for systemic traits such as type 2 diabetes, schizophrenia, cancer, and bone mineral density. These results potentially suggest that peripheral immune cell dysregulation is directly involved in the pathogenesis of systemic diseases, or that they may share cell-level genetic regulation with other cell types in disease-relevant tissues. These two hypotheses can be observed in the polygenic enrichment patterns observed in the single-cell disease relevance score (scDRS) analysis, which shows that polygenic signatures of systemic disease were indeed observed across PBMC cells, but to a lesser extent compared to traits directly related to immune dysregulation and peripheral blood composition. Given that nearly half of cis-eQTLs are shared across tissues[20], these findings implicate that large-scale sc-eQTL maps may provide some insights into causal biology of systemic diseases in other tissues with similar expression of disease-relevant genes or with shared genetic regulation.

At the cell type level, we found striking enrichment of immune-mediated disease associations in dendritic cell (DC) populations. In Crohn's disease, for example, multiple DC subsets (cDC1, cDC2, ASDC) showed strong polygenic enrichment and MR-supported causal associations, consistent with prior evidence that DCs accumulate and become activated in inflamed intestinal tissue[9]. In contrast, COVID-19 genetic risk was specifically enriched in plasmacytoid DCs (pDCs), aligning with their established role in antiviral immunity and rapid interferon production[11]. Focusing on B cells in the context of SLE, we found SLE-enriched cells display significantly a higher cell function score for cellular response to type II interferon, a B cell-intrinsic mechanism implicated in SLE pathogenesis via autoimmune response due to dysregulated germinal centre[38]. These findings suggest that large-scale sc-eQTL data, when integrated with GWAS and functional annotation of relevant biological context, can resolve the cell type-specific contributions of immune populations to disease even in the absence of disease-context tissue sampling.

Translationally, our data show that causal gene–trait relationships derived from single-cell MR are predictive of clinical development success. By intersecting MR results with drug target and trial data from the Open Targets Platform, we found that target–indication pairs supported by single-cell MR were 3.3 times more likely to reach regulatory approval. These pairs also showed higher evidence scores across both genetic and non-genetic data sources and were more likely to display concordant direction of effect with the mechanism of action of approved or late-phase drugs. Our framework successfully recapitulated known therapeutic targets, including *JAK2* and *TNF* for Crohn's disease, *IL6R* for rheumatoid arthritis, *APP* for Alzheimer's disease, and *GLP1R* for type 2 diabetes, while nominating cell type-specific genes with strong genetic support for new indications. In addition, our data show more than half of targets tested in clinical trials (including 151 that are already approved) had single-cell MR support for at least one tested indication, implicating opportunities for drug repurposing.

To highlight the utility of cell-type-resolved MR for identifying both canonical and novel therapeutic targets, we further explored 510 genes associated with Crohn's disease as a case study. We identified 510 MR-significant genes, including those with well-established

roles such as *NCF4*, *ATG16L1*, and *IL23R*, as well as less characterised candidates such as *ZBTB38*. The transcriptional repressor *ZBTB38* exhibited a positive causal effect in T and B cell subsets and was independently upregulated in disease-affected colon tissue. *ZBTB38* has been linked to Crohn's disease[39] and other inflammatory diseases[40,41], however its functional role in T and B cells has not been explored. Our findings here offer a testable hypothesis that *ZBTB38* may modulate cell type-specific programs relevant to disease pathogenesis, supported by differential expression in disease. A second example, *NCF4,* is a known risk gene that encodes a subcomponent of the NADPH complex, playing a critical role in oxidative stress and antimicrobial function[42]. In Crohn's disease, *NCF4* exhibited a positive effect in B memory cells, in contrast to a negative effect in other cell types including B naive cells. Interestingly, independent eQTL data show that the top eSNP in B memory cells, which has a uniquely positive effect, is a fine-mapped SNP with a negative eQTL effect in monocytes, macrophages, neutrophils, but a positive splicing QTL (sQTL) effect in B-cell derived lymphoblastoid cell lines[24,43]. Many eQTL effects are explained by splicing QTLs[44,45], and these results highlight the need for long-read sequencing to resolve cell type specific sQTLs and explain novel causal associations. In this case study, we form links between MR results within diseases as well as independent, orthogonal sources of evidence such as differential gene expression[46].

We also identified MR-supported associations that may inform mechanisms of action for existing therapies. For example, for Crohn's disease, we found a positive causal association of *IL23R* in γδ T cells and a negative (protective) association of *IL12Rβ2* in multiple immune cell types, while *IL12Rβ1* showed no significant effect. These observations are consistent with clinical evidence that ustekinumab (targeting the shared *IL12*/*IL23* p40 subunit, blocking the *IL23R*/*IL12Rβ1* receptor complex) acts predominantly through *IL23* blockade, and may help explain the increased efficacy of *IL23*-specific therapies like guselkumab[47–49]. Our data suggest that targeted modulation of *IL23R* and sparing of *IL12RB2* may optimise therapeutic efficacy while reducing off-target effects.

Our study has several limitations. First, MR estimates are subject to bias from overestimation in sc-eQTL discovery (winner's curse) and residual pleiotropy not fully accounted for by the HEIDI test. Second, PBMCs may not capture causal regulation in disease-relevant tissues or tissue-resident immune compartments. Third, the statistical power of our study may be limited for rare cell types genes with low expression. While we downsampled abundant cell types to reduce bias in the polygenic enrichment analysis, sensitivity analyses suggest this had minimal impact. Furthermore, OpenTargets may not capture all active drug development programs, and many apparently negative results may reflect the absence of evidence rather than evidence of absence. Depending on the particular disease, signals may not be detected if their key causal effects are mediated in non-peripheral immune cells, or tissue-specific cells such as epithelial or stromal cells. Finally, functional validation of hypotheses is essential to confirm the causal relevance of newly implicated genes and their therapeutic potential.

In summary, we present a large-scale, cell type-resolved atlas of causal gene–trait associations by integrating single-cell eQTL mapping with GWAS through Mendelian

554 randomisation. Our results highlight extensive and cell-specific polygenic contributions to
555 complex traits, identify new regulatory mechanisms in disease, and demonstrate that MR-
556 informed cell type-specific targets are predictive of drug development success. This resource
557 provides a powerful foundation for understanding the molecular underpinnings of complex
558 disease and for guiding precision therapeutic strategies.

Methods

Data sources

Single-cell eQTL

To perform single-cell MR analysis, we used genetic instruments derived from a large-
scale single-cell expression quantitative trait loci (sc-eQTL) association analysis from Phase 1
of the TenK10K project[15]. This dataset comprises matched whole-genome sequencing (WGS)
and single-cell RNA-sequencing (scRNA-seq) data from 1,925 individuals of European
ancestry from Tasmanian Ophthalmic Biobank (TOB) and the BioHEART study cohort,
covering over 5 million peripheral blood mononuclear cells (PBMCs) across 28 immune cell
types. The cell types were identified using a combined approach that uses scPred[50] and sc-
HPL[51] with Azimuth PBMC reference dataset[52].
The sc-eQTL association test was performed separately in each of the 28 cell types
using a Poisson mixed model for single-cell counts implemented in SAIGE-QTL[53] with the
following covariates: sex and age of the individuals, 7 genotype PCs, 5 cell type-specific
expression PCs, cohort status (TOB or BioHEART), percentage of counts from mitochondrial
genes and total counts. For each gene, common genetic variants (minor allele frequency >1%)
within *cis*-region of the gene, defined as 100 kbp window upstream and downstream site of the
tested eGene bodies based on ENCODE v44 hg38 coordinates, were tested for association with
expression level of the gene measured in raw counts. A total of 12,874,224 variants were
included in the analysis, which yielded 154,932 common variant sc-eQTL across 17,674 unique
eGenes across cell types at FDR 5%.

Genome-wide association study of complex traits

To perform MR, MAGMA and scDRS, analyses, we used publicly accessible genome-
wide association results of 100 complex diseases and biological traits across 10 phenotype
categories: Blood (26 traits)[54], Skeletal traits (5 traits)[55,56], Cancer (31 diseases)[57–66], Immune
(9 diseases)[67–73], Viral infection (6 diseases)[74–76], Cardiometabolic (6 diseases)[77–83], Neurologic
(3 diseases)[84–86], Psychiatric (7 diseases)[87–91], Respiratory (3 diseases)[92–94], and Other (4
diseases)[95–98]. For each trait, we obtained GWAS summary statistics from public repositories.
Summary statistics were harmonised to the TenK10K study by matching variants'
genomic coordinates and alleles, performing conversion to hg38 with liftOver and
harmonisation of minor and major alleles based on allele frequency in individual-level
genotype from the TenK10K study. To ensure consistency of variants' allele frequency and

linkage disequilibrium pattern with TenK10K sc-eQTL dataset, analysis was limited to GWAS
performed in European ancestries. If unreported in the GWAS summary statistics, values such
as the beta value as log(OR), standard error and p-values were derived from other reported
values. The effective GWAS sample size for binary disease traits presented in **Figure 1c** was
calculated as 4 / (1/number of cases + 1/number of controls). More details of each trait, GWAS
data source, reference, and number of samples are provided in **Supplementary Table 2**.
598

Mendelian randomisation analysis

To identify genes associated with disease and biomarker traits in PBMC cell types, we
performed a multi-instrument Mendelian randomisation (MR) analysis using the SMR
approach as implemented in the SMR v1.3.1 software package[13]. Genetic instruments for MR
were selected from common variants within the *cis*-region of the tested gene bodies passing
cell type-specific thresholds. The cell type-specific thresholds were derived from the maximum
P-value across sc-eQTL for eGenes identified at FDR <5% in the TenK10K phase I study[15].
Following the default parameter of the SMR software[14], variants that are not available in the
GWAS summary statistics of tested phenotype or those with allele frequency difference > 0.2
are excluded prior to the instrument selection steps. In the MR analysis, we pruned variants
that are highly correlated (linkage disequilibrium (LD) r^2 > 0.9) with the top sc-eQTL within
the region, and used set-based approximation accounting for residual LD to combine MR
estimates from the remaining variants, with *P*-value derived using Saddlepoint approximation.
MR analysis was performed by modelling the effect of increased gene expression level on
disease risk or trait levels so that a positive association implies a trait-increasing (or risk-
increasing) effect and a negative association implies a trait-decreasing (or protective) effect.

To adjust for multiple testing, MR *P*-values were adjusted for false discovery rate
(FDR) by calculating *Q*-values based on *P*-values distribution across cell type-gene
combinations per trait with the *qvalue* R package[99]. To minimise confounding by pleiotropic
effects on other genes, we further performed a test for heterogeneity in dependent instruments
(HEIDI)[13] for each MR test we performed. An MR estimate with a Q < 0.05 and a P_{HEIDI} ≥
0.01 were considered as evidence of a causal association.

The comparison with eQTLGen was performed using publicly available pre-formatted
SMR summary statistics from eQTLgen Consortium[17], downloaded from
https://eqtlgen.org/cis-eqtls.html. Consistent with the original publication, we used a threshold
of P_{eQTL} < 2.02×10^{-5} to select genetic instrument for MR. Multiple testing correction for
MRwas performed consistently with the TenK10K study.

Identification of GWAS genes

To identify GWAS genes for comparison with MR results, we performed a gene-level
aggregation of single-variant estimates from GWAS summary statistics using MAGMA[16]. The

aggregation for each gene was performed across variants within the transcription start and end
sites of the gene (based on ENCODE v44 hg38 coordinates) using a SNP-wise model with
linkage disequilibrium between variants modeled using reference data TenK10K phase I
individual-level genotype. *P*-value for a gene-trait association was derived using mean chi-
squared statistics by approximation of known sampling distribution. To account for multiple
testing, we calculated Q-values across all analytical sets. Genes associated with a trait at Q <
0.05 were considered as putative GWAS genes for the trait.

Single-cell polygenic enrichment of complex traits

We utilized the single-cell disease relevance score (scDRS)[10] method to quantify
polygenic enrichment of complex traits at both individual-cell and cell-type levels. scDRS
integrates single-cell gene expression profiles with GWAS summary statistics to associate
individual cells to the GWAS trait, by testing overexpression of trait-relevant genes derived
from GWAS in a given cell relative to other genes with similar expression profile across all
cells. To run scDRS for each trait, we first extracted the top 1,000 trait-associated genes based
on *Z*-score derived from the MAGMA analysis. Next, we used scDRS to compute the aggregate
expression of the associated genes in each cell, weighted by the GWAS MAGMA *Z*-score and
inversely weighted by gene-specific technical covariates in the single-cell data, using the mean-
variance model. To compute cell-level *P*-value for overexpression of trait-relevant genes, we
followed scDRS method to first generate 1,000 sets of cell-specific raw control scores
computed using Monte Carlo (MC) samples of matched control gene sets (matching gene set
size, mean expression and expression variance of the selected genes). The *P*-value was then
derived by comparing normalised trait scores against normalised control scores based on the
empirical distribution of the pooled normalised control scores across all control gene sets and
all cells.

Single-cell RNA sequencing data to perform scDRS analysis were extracted from ~5
million PBMCs that passed through the processing and quality control pipeline in the TenK10K
phase I study[15]. The cell-level scoring in scDRS was performed using sex, age, number of
genes, and cohort (TOB and BioHEART) as covariates. To manage computational efficiency
and account for variations in cell type proportions, we randomly sampled a maximum of 10,000
cells for each of the 28 immune cell types in the TenK10K phase 1 study, resulting in 229,239
total sampled cells. To test the robustness of this sampling strategy, we repeated this procedure
using Crohn's disease as an example with an alternative sampling strategy by taking 10% of
cells from each cell type.

Quantification of cell function score in B cells

We computed cell function scores in B cells as cell states using scDeepID, a flexible
multi-task transformer that leverages different biological pathway databases as guides to train
the model. First, we trained a scDeepID model with 539,820 B cells (including B naive, B
intermediate, and B memory cells) from TenK10K phase 1 single-cell RNA sequencing data.

The training used expression features of 2,351 highly variable genes selected with Scanpy
function highly_variable_genes (min_mean=0.0123, max_mean=3, min_disp=0.5) with
human Biological Process Gene Ontology (GOBP) database as a guide, filtered to the top 400
most informative GOBP pathways based on the presence of pathway genes in the highly
variable gene list. We then extracted the attention-based latent space for UMAP representation,
and extracted the cell function scores followed by transformation of each cell function score to
approximate a normal distribution with a zero mean and one unit variance.

As a proof-of-concept to explore the function of cells that are enriched for specific
phenotypes, we intersected scDeepID cell function score with scDRS score for systemic lupus
erythematosus (scDRS$_{SLE}$) amongst 30,000 subsampled B cells used in the scDRS analysis.
We first grouped these cells into SLE-enriched cells (cell-level $P_{scDRS-SLE}$) and non-SLE-
enriched cells, and compared mean cell function scores between the two groups using a one-
sided T-test for each pathway under analysis followed by FDR correction.

Estimating the support of single-cell genetics for drug target validation

To evaluate the utility of single-cell genetics for drug target identification, we cross-
referenced our cell-type resolved MR results with a target-evidence association score and drug
development activity dataset sourced from Open Targets Platform (OTP) [24] version 25.06.
Analysis were limited to a set of 12,873 protein-coding genes tested in the MR analysis and 57
diseases with at least one matching indication available in the Open Targets Platform database,
resulting in a total of 733,761 possible pairs of target (gene) and indication (disease) – the
target-indication universe in this study. We used Ensembl gene ID to match tested genes to
OTP targets, and used Experimental Factor Ontology (EFO) ID to match tested phenotypes to
OTP indications.
First, we extracted drug development activity data in OTP (sourced from ChEMBL[25])
and calculated the maximum evidence score in OTP for every target-indication pair. Following
ChEMBL classification, we categorised the evidence score into the following:

Maximum Clinical Development Stage	Evidence Score
Phase I	0.1
Phase II	0.2
Phase III	0.7
Phase I+	0.1 or more
Phase II+	0.2 or more
Phase III+	0.7 or more
Approved	1

For every category, we computed the 2x2 intersection between target-indication inside
or outside the category and target-indication with or without MR support, resulting in four
possible combinations: in the category & with MR support, in the category & without MR
support, outside the category & with MR support, and outside the category & without MR
support. Using this 2x2 contingency table, we then computed the odds ratio for being in the
category, comparing between target-indication pairs with and without MR support. P-value
and 95% lower confidence interval were calculated using a one-sided Fisher's exact test
implemented in *fisher.test()* R function. For this analysis, MR support was defined as a
significant MR association ($Q_{MR} < 0.05$ and $P_{HEIDI} \geq 0.01$) in at least one cell type
under analysis.

Second, for every matched target-indication pair under analysis, we extracted the
overall OTP evidence score which quantifies aggregated evidence from data sources of genetic
association, somatic mutation, known drug, affected pathway, literature, RNA expression, and
animal model. We took the maximum of direct (evidence referring directly to indication ID)
and indirect association score (evidence referring to indication ID or any of its descendant IDs
in EFO). The association score takes a value between 0 and 1, where a higher score indicates
more evidence supporting the target-indication association relative to a theoretical maximum.
We computed the mean score of target-indication with and without MR support, and tested the
difference using a two-sample Welch's T-test implemented in *t.test()* R function. We then
extracted the evidence score stratified by data score, computed the genetic evidence score
(unweighted mean of scores from genetic association sources) and non-genetic evidence
(unweighted mean of scores from non-genetic association sources), and repeated the test
procedures for the two evidence sources.

Third, we assessed the concordance between MR-predicted effect direction and drug
mechanism across clinical development phases. The MR-predicted effect direction for a target-
indication pair was derived by taking the majority of effect directions across cell types with
significant MR associations. To remove ambiguity, target-indication with equal number of
positive and negative effects across cell types were excluded from the analysis. The drug
mechanism effects were extracted from ChEMBL drug data in OTP, and matched with
ChEMBL ID of drug with maximum clinical development phase for a given target-indication
pair.

730
731

Crohn's disease case study

We extracted all MR associations for Crohn's disease which passed the discovery
threshold of FDR-adjusted $Q < 5\%$ and $P_{HEIDI} > 0.01$.. For each unique MR gene identified, we
constructed a Boolean annotation (TRUE / FALSE) based on membership in: 1) the canonical
gene list, 2) the drug target gene list 3) the drug target pathways, 4) cell type-specific MR
association (whether the MR association is only identified in one cell type), 5) discordance of
MR effect direction in at least two cell types, and 6) differentially expressed in Crohn's disease
colon tissue where the major cell types are matched (**Supplementary Table 13**).

Canonical genes from Crohn's disease were downloaded from a systematic review of
genes associated with Crohn's disease[100] The full list (n = 1,172) was filtered to belong to
Categories "Experimental evidence of variant", "Other evidences of genetic alterations",
"Treatment Response" , "Biologically related but no evidence of mutation", with a Document
Score >= 8 and Abstract Number >= 10, resulting in a list of 49 genes (**Supplementary Table**
15). The drug target genes were extracted from review papers[101,102], and the drug pathway
genes (IL23/12, ITGA4, JAK/STAT, TNF) were extracted from GSEA platform[103,104]
following the approach described previously[71] (**Supplementary Table 16**). The list of
differentially expressed genes was derived from an external dataset of single-cell RNA
sequencing in intestinal tissues from 46 Crohn's disease patients and 25 healthy controls,
comparing both inflamed and non-inflamed disease tissue with healthy tissue.[33] To derive this
annotation, we extracted differentially expressed genes in the colon (pre-computed Discrete
FDR < 0.05) across immune cell types. We harmonised the original cell type annotation with
the TenK10K cell type annotation used in this study by matching major cell types
(**Supplementary Table 17**). We then identified MR and DEG genes in matched major cell
types, and checked for concordance of direction of effect by comparing the beta sign between
MR and the Discrete model of DEG (**Supplementary Table 14**). This generated multiple
combinations of gene-major cell type pairs, based on unique combinations of original MR cell
types and DEG cell types. 'All concordant' corresponds to cases where every gene-MR cell
type-DEG cell type set has a matched direction of effect between MR and DEG. 'All
discordant' corresponds to cases where every gene-MR cell type-DEG cell type set has an
unmatched direction of effect between MR and DEG. 'Mixed concordance' corresponds to
genes which have discordant directions between or within major cell types.
To evaluate expression of the genes of interest in colon tissue (**Figure 5d**), we extracted
sc-RNAseq data from colon tissue of Crohn's disease patients[33], downloaded from
CELLxGENE[105]. We present the gene expression as normalised counts on the original Uniform
Manifold Approximation and Projection (UMAP) embedding using Scanpy, stratified by
'Type' into "Healthy", "Non-inflamed Crohn's disease", and "Inflamed Crohn's disease" and
filtered to immune cell types with matched major cell types annotation in the TenK10K. The
original cell annotation and distribution of cells before and after filtering is presented in
Supplementary Figure 15.

Author contribution

A.H., A.S., R.T., and J.E.P. designed the overall study. A.H., A.S., R.T., B.B., and J.E.P. contributed to the initial writing of the manuscript. A.H. and A.S. performed single-cell MR analysis. A.H. designed and performed MAGMA, scDRS, and drug target support analyses. R.T. designed and performed the proof-of-concept analysis in Crohn's disease. B.B. and A.S.E.C. performed the sc-eQTL mapping in the TenK10K led by J.E.P., with genotype data processing led by K.M.dL. and D.G.M. A.S., H.A.T., and A.H. processed GWAS summary statistics. E.S. and E.S.Z. contributed to the sample collection, processing, and generation of single-cell RNA sequencing data. A.X, J.F., and P.C.A. provided input for single-cell MR and scDRS analysis. H.L.H. designed and performed the cell function analysis with scDeepID. A.H., A.S., B.B., R.T., and H.L.H. contributed to the design and generation of figures, tables, and computational pipeline for analysis. G.A.F. led the BioHEART study and A.W.H. led the Tasmanian Ophthalmic Biobank study, of which samples were included in the sc-eQTL mapping. J.E.P. contributed to funding acquisition and supervision for the study. All authors reviewed and approved the final version of the manuscript.

Acknowledgements

The authors acknowledge the use of computational resources and support from the Australian National Computing Infrastructure and the Data Science Platform of the Garvan Institute of Medical Research. The authors acknowledge contributions from Prof. Peter Croucher's Lab and Dr. John Kemp's Lab for access to GWAS summary statistics of estimated heel bone mineral density.

Ethics Statement

The Human Research Ethics Committee of St Vincent's Hospital gave ethical approval for this work. The National Statement on Ethical Conduct in Human Research of the National Health and Medical Research Council gave ethical approval for this work.

Competing interests

D.G.M. is a paid advisor to Insitro and GSK, and receives research funding from Google and Microsoft, unrelated to the work described in this manuscript. G.A.F reports grants from National Health and Medical Research Council (Australia), Abbott Diagnostic, Sanofi, Janssen Pharmaceuticals, and NSW Health, and honorarium from CSL, CPC Clinical Research, Sanofi, Boehringer-Ingelheim, Heart Foundation, and Abbott. G.A.F serves as Board Director for the Australian Cardiovascular Alliance (past President), Executive Committee Member for CPC Clinical Research, Founding Director and CMO for Prokardia and Kardiomics, and Executive Committee member for the CAD Frontiers A2D2 Consortium. In addition, G.A.F serves as CMO for the non-profit, CAD Frontiers, with industry partners including, Novartis, Amgen, Siemens Healthineers, ELUCID, Foresite Labs LLC, HeartFlow, Canon, Cleerly, Caristo, Genentech, Artyra, and Bitterroot Bio, Novo Nordisk and Allelica. G.A.F also reports the following patents: "Patent Biomarkers and Oxidative Stress" awarded USA May 2017 (US9638699B2) issued to Northern Sydney Local Health District, "Use of P2X7R antagonists in cardiovascular disease" PCT/AU2018/050905 licensed to Prokardia, "Methods for treatment and prevention of vascular disease" PCT/AU2015/000548 issued to The University of Sydney/Northern Sydney Local Health District, "Methods for predicting coronary artery disease" AU202290266 issued to The University of Sydney, and the patent "Novel P2X7 Receptor Antagonists" PCT/AU2022/051400 (23.11.2022), International App No: WO/2023/092175 (01.06.2023), issued to The University of Sydney.

Data availability

The main single-cell MR association results will be made publicly available via Zenodo website prior to acceptance.

Code availability

Analysis code will be made publicly available at https://github.com/powellgenomicslab/tenk10k-causal-paper

References

1. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating the dark road from association to function. *Am. J. Hum. Genet.* **93**, 779–797 (2013).

2. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits: From polygenic to omnigenic. *Cell* **169**, 1177–1186 (2017).

3. Yazar, S. *et al.* Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. *Science* **376**, eabf3041 (2022).

4. Nathan, A. *et al.* Single-cell eQTL models reveal dynamic T cell state dependence of disease loci. *Nature* **606**, 120–128 (2022).

5. Cuomo, A. S. E., Nathan, A., Raychaudhuri, S., MacArthur, D. G. & Powell, J. E. Single-cell genomics meets human genetics. *Nat. Rev. Genet.* (2023) doi:10.1038/s41576-023-00599-5.

6. Elmentaite, R. *et al.* Cells of the human intestinal tract mapped across space and time. *Nature* **597**, 250–255 (2021).

7. Perez, R. K. *et al.* Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. *Science* **376**, eabf1970 (2022).

8. Bryois, J. *et al.* Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. *Nat. Neurosci.* **25**, 1104–1112 (2022).

9. Natri, H. M. *et al.* Cell-type-specific and disease-associated expression quantitative trait loci in the human lung. *Nat. Genet.* **56**, 595–604 (2024).

10. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-seq data. *Nat. Genet.* **54**, 1572–1580 (2022).

11. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. *Nat. Genet.* **54**, 1479–1492 (2022).

12. Porcu, E. *et al.* Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants of complex and clinical traits. *Nat. Commun.* **10**, 3300 (2019).

13. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nature Genetics* **48**, 481–487 (2016).

14. Wu, Y. *et al.* Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nat. Commun.* **9**, 918 (2018).

15. Cuomo, A. S. E. *et al.* Impact of Rare and Common Genetic Variation on Cell Type-Specific Gene Expression. *Genetic and Genomic Medicine* (2025).

16. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).

17. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53**, 1300–1310 (2021).

18. Middel, P., Raddatz, D., Gunawan, B., Haller, F. & Radzun, H.-J. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. *Gut* **55**, 220–227 (2006).

19. Collin, M. & Bigley, V. Human dendritic cell subsets: an update. *Immunology* **154**, 3–20 (2018).

20.   Swiecki, M. & Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. *Nat. Rev.*
Immunol. **15**, 471–485 (2015).

21.   Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic
evidence on clinical success. *Nature* **629**, 624–629 (2024).

22.   Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications.
Nature Genetics **47**, 856–860 (2015).

23.   Dann, E. *et al.* Estimating the impact of single-cell RNA sequencing of human tissues on drug
target validation. *medRxiv* 2024.04.04.24305313 (2024) doi:10.1101/2024.04.04.24305313.

24.   Buniello, A. *et al.* Open Targets Platform: facilitating therapeutic hypotheses building in drug
discovery. *Nucleic Acids Res* **53**, D1467–D1475 (2025).

25.   Zdrazil, B. *et al.* The ChEMBL Database in 2023: a drug discovery platform spanning multiple
bioactivity data types and time periods. *Nucleic Acids Res.* **52**, D1180–D1192 (2024).

26.   Hampel, H. *et al.* The amyloid-β pathway in Alzheimer's disease. *Mol. Psychiatry* **26**, 5481–
5503 (2021).

27.   Zheng, Z. *et al.* Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. *Signal*
Transduct. Target. Ther. **9**, 234 (2024).

28.   Lincoff, A. M. *et al.* Semaglutide and cardiovascular outcomes in obesity without diabetes. *N.*
Engl. J. Med. **389**, 2221–2232 (2023).

29.   Ryan, D. H. *et al.* Long-term weight loss effects of semaglutide in obesity without diabetes in the
SELECT trial. *Nat. Med.* **30**, 2049–2057 (2024).

30.   Roda, G. *et al.* Crohn's disease. *Nat. Rev. Dis. Primers* **6**, 22 (2020).

31.   Torres, J., Mehandru, S., Colombel, J.-F. & Peyrin-Biroulet, L. Crohn's disease. *Lancet* **389**,
1741–1755 (2017).

32.   de Lange, K. M. & Barrett, J. C. Understanding inflammatory bowel disease via
immunogenetics. *J. Autoimmun.* **64**, 91–100 (2015).

33.   Kong, L. *et al.* The landscape of immune dysregulation in Crohn's disease revealed through
single-cell transcriptomic profiling in the ileum and colon. *Immunity* **56**, 444–458.e5 (2023).

34.   Timpson, N. J., Greenwood, C. M. T., Soranzo, N., Lawson, D. J. & Richards, J. B. Genetic
architecture: the shape of the genetic contribution to human traits and disease. *Nat. Rev. Genet.*
19, 110–124 (2018).

35.   Wray, N. R., Wijmenga, C., Sullivan, P. F., Yang, J. & Visscher, P. M. Common disease is more
complex than implied by the core gene omnigenic model. *Cell* **173**, 1573–1580 (2018).

36.   Mackay, T. F. C. & Anholt, R. R. H. Pleiotropy, epistasis and the genetic architecture of
quantitative traits. *Nat. Rev. Genet.* **25**, 639–657 (2024).

37.   Stankey, C. T. *et al.* A disease-associated gene desert directs macrophage inflammation through
ETS2. *Nature* **630**, 447–456 (2024).

38.   Jackson, S. W. *et al.* B cell IFN-γ receptor signaling promotes autoimmune germinal centers via
cell-intrinsic induction of BCL-6. *J. Exp. Med.* **213**, 733–750 (2016).

39.   Burdett, T. *et al.* GWAS Catalog. https://www.ebi.ac.uk/gwas/genes/ZBTB38.

40. Ocskó, T. *et al.* Transcription factor Zbtb38 downregulates the expression of anti-inflammatory
IL1r2 in mouse model of rheumatoid arthritis. *Biochim. Biophys. Acta Gene Regul. Mech.* **1861**,
1040–1047 (2018).

41. Yan, M. *et al.* Dynamic regulatory networks of T cell trajectory dissect transcriptional control of
T cell state transition. *Mol. Ther. Nucleic Acids* **26**, 1115–1129 (2021).

42. He, C. *et al.* NCF4 dependent intracellular reactive oxygen species regulate plasma cell
formation. *Redox Biol.* **56**, 102422 (2022).

43. Buil, A. *et al.* Gene-gene and gene-environment interactions detected by transcriptome sequence
analysis in twins. *Nat. Genet.* **47**, 88–91 (2015).

44. Garrido-Martín, D., Borsari, B., Calvo, M., Reverter, F. & Guigó, R. Identification and analysis
of splicing quantitative trait loci across multiple tissues in the human genome. *Nat. Commun.* **12**,
727 (2021).

45. Yamaguchi, K. *et al.* Splicing QTL analysis focusing on coding sequences reveals mechanisms
for disease susceptibility loci. *Nat. Commun.* **13**, 4659 (2022).

46. Munafò, M. R., Higgins, J. P. T. & Smith, G. D. Triangulating evidence through the inclusion of
genetically informed designs. *Cold Spring Harb. Perspect. Med.* **11**, a040659 (2021).

47. Luo, J. *et al.* Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. *J. Mol.*
Biol. **402**, 797–812 (2010).

48. Ma, C., Panaccione, R., Khanna, R., Feagan, B. G. & Jairath, V. IL12/23 or selective IL23
inhibition for the management of moderate-to-severe Crohn's disease? *Best Pract. Res. Clin.*
Gastroenterol. **38-39**, 101604 (2019).

49. Verstockt, B. *et al.* IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. *Nat. Rev.*
Gastroenterol. Hepatol. **20**, 433–446 (2023).

50. Alquicira-Hernandez, J., Sathe, A., Ji, H. P., Nguyen, Q. & Powell, J. E. scPred: accurate
supervised method for cell-type classification from single-cell RNA-seq data. *Genome Biol.* **20**,
264 (2019).

51. Michielsen, L., Reinders, M. J. T. & Mahfouz, A. Hierarchical progressive learning of cell
identities in single-cell data. *Nat. Commun.* **12**, 2799 (2021).

52. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29
(2021).

53. Zhou, W. *et al.* Efficient and accurate mixed model association tool for single-cell eQTL
analysis. *Genetic and Genomic Medicine* (2024).

54. Vuckovic, D. *et al.* The polygenic and monogenic basis of blood traits and diseases. *Cell* **182**,
1214–1231.e11 (2020).

55. Chai, R. C. *et al.* Multiscale analysis and functional validation of the cellular and genetic
determinants of skeletal disease. *Genetics* (2024).

56. Miao, J. *et al.* Valid inference for machine learning-assisted genome-wide association studies.
Nat. Genet. **56**, 2361–2369 (2024).

57. Rashkin, S. R. *et al.* Pan-cancer study detects genetic risk variants and shared genetic basis in
two large cohorts. *Nat. Commun.* **11**, 4423 (2020).

58. Fernandez-Rozadilla, C. *et al.* Deciphering colorectal cancer genetics through multi-omic
analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. *Nat.*
Genet. **55**, 89–99 (2023).

59. McKay, J. D. *et al.* Large-scale association analysis identifies new lung cancer susceptibility loci
and heterogeneity in genetic susceptibility across histological subtypes. *Nat. Genet.* **49**, 1126–
1132 (2017).

60. Adolphe, C. *et al.* Genetic and functional interaction network analysis reveals global enrichment
of regulatory T cell genes influencing basal cell carcinoma susceptibility. *Genome Med.* **13**, 19
(2021).

61. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population.
Nature **613**, 508–518 (2023).

62. Verma, A. *et al.* Diversity and scale: Genetic architecture of 2068 traits in the VA Million
Veteran Program. *Science* **385**, eadj1182 (2024).

63. Zhang, H. *et al.* Genome-wide association study identifies 32 novel breast cancer susceptibility
loci from overall and subtype-specific analyses. *Nat. Genet.* **52**, 572–581 (2020).

64. Wang, A. *et al.* Characterizing prostate cancer risk through multi-ancestry genome-wide
discovery of 187 novel risk variants. *Nat. Genet.* **55**, 2065–2074 (2023).

65. Kar, S. P. *et al.* Genome-wide analyses of 200,453 individuals yield new insights into the causes
and consequences of clonal hematopoiesis. *Nat. Genet.* **54**, 1155–1166 (2022).

66. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat.*
Genet. **53**, 1415–1424 (2021).

67. Chiou, J. *et al.* Interpreting type 1 diabetes risk with genetics and single-cell epigenomics.
Nature **594**, 398–402 (2021).

68. Bentham, J. *et al.* Genetic association analyses implicate aberrant regulation of innate and
adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat. Genet.* **47**,
1457–1464 (2015).

69. Ishigaki, K. *et al.* Multi-ancestry genome-wide association analyses identify novel genetic
mechanisms in rheumatoid arthritis. *Nat. Genet.* **54**, 1640–1651 (2022).

70. Stuart, P. E. *et al.* Transethnic analysis of psoriasis susceptibility in South Asians and Europeans
enhances fine-mapping in the MHC and genomewide. *HGG Adv.* **3**, 100069 (2022).

71. de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of multiple
integrin genes in inflammatory bowel disease. *Nat. Genet.* **49**, 256–261 (2017).

72. International Multiple Sclerosis Genetics Consortium (IMSGC) *et al.* Analysis of immune-
related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat. Genet.* **45**, 1353–
1360 (2013).

73. Budu-Aggrey, A. *et al.* European and multi-ancestry genome-wide association meta-analysis of
atopic dermatitis highlights importance of systemic immune regulation. *Nat. Commun.* **14**, 6172
(2023).

74. COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture
of COVID-19. *Nature* **621**, E7–E26 (2023).

75. Lammi, V. *et al.* Genome-wide association study of long COVID. *Nat. Genet.* **57**, 1402–1417

(2025).

76. Bian, S. *et al.* Genetic determinants of IgG antibody response to COVID-19 vaccination. *Am. J.*
Hum. Genet. **111**, 181–199 (2024).

77. Suzuki, K. *et al.* Multi-ancestry genome-wide study in >2.5 million individuals reveals
heterogeneity in mechanistic pathways of type 2 diabetes and complications. *medRxiv* (2023)
doi:10.1101/2023.03.31.23287839.

78. Zhao, C., Ma, T., Cheng, X., Zhang, G. & Bai, Y. Genome-wide association study of
cardiometabolic multimorbidity in the UK Biobank. *Clin. Genet.* **106**, 72–81 (2024).

79. Adlam, D. *et al.* Genome-wide association meta-analysis of spontaneous coronary artery
dissection identifies risk variants and genes related to artery integrity and tissue-mediated
coagulation. *Nat. Genet.* **55**, 964–972 (2023).

80. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for
coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815 (2022).

81. Zheng, S. L. *et al.* Genome-wide association analysis provides insights into the molecular
etiology of dilated cardiomyopathy. *Nat. Genet.* **56**, 2646–2658 (2024).

82. Henry, A. *et al.* Genome-wide association study meta-analysis provides insights into the etiology
of heart failure and its subtypes. *Nat. Genet.* **57**, 815–828 (2025).

83. Surakka, I. *et al.* Multi-ancestry meta-analysis identifies 2 novel loci associated with ischemic
stroke and reveals heterogeneity of effects between sexes and ancestries. *bioRxiv* (2022)
doi:10.1101/2022.02.28.22271647.

84. Kim, J. J. *et al.* Multi-ancestry genome-wide association meta-analysis of Parkinson's disease.
Nat. Genet. **56**, 27–36 (2024).

85. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related
dementias. *Nat. Genet.* **54**, 412–436 (2022).

86. Hautakangas, H. *et al.* Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci
and subtype-specific risk alleles. *Nat. Genet.* **54**, 152–160 (2022).

87. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic
architecture and implicate several cognitive domains. *Nat. Genet.* **55**, 198–208 (2023).

88. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat.*
Genet. **51**, 431–444 (2019).

89. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
schizophrenia. *Nature* **604**, 502–508 (2022).

90. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid
psychiatric disorders using genome-wide analyses. *Nat. Med.* **29**, 1832–1844 (2023).

91. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases
provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).

92. Tsuo, K. *et al.* Multi-ancestry meta-analysis of asthma identifies novel associations and
highlights the value of increased power and diversity. *Cell Genom.* **2**, 100212 (2022).

93. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across
human disease. *Cell Genom.* **2**, 100192 (2022).

94. Allen, R. J. *et al.* Genome-wide association study of susceptibility to idiopathic pulmonary
fibrosis. *Am. J. Respir. Crit. Care Med.* **201**, 564–574 (2020).

95. McDonald, M.-L. N. *et al.* Novel genetic loci associated with osteoarthritis in multi-ancestry
analyses in the Million Veteran Program and UK Biobank. *Nat. Genet.* **54**, 1816–1826 (2022).

96. Day, F. *et al.* Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests
shared genetic architecture for different diagnosis criteria. *PLoS Genet.* **14**, e1007813 (2018).

97. Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain and
inflammatory conditions. *Nat. Genet.* **55**, 423–436 (2023).

98. Lo Faro, V. *et al.* Novel ancestry-specific primary open-angle glaucoma loci and shared biology
with vascular mechanisms and cell proliferation. *Cell Rep. Med.* **5**, 101430 (2024).

99. John D. Storey with contributions from Andrew J. Bass, A. A. D. R. *Qvalue*. (Bioconductor,
2017). doi:10.18129/B9.BIOC.QVALUE.

100. Garza-Hernandez, D. *et al.* A systematic review and functional bioinformatics analysis of genes
associated with Crohn's disease identify more than 120 related genes. *BMC Genomics* **23**, 302
(2022).

101. Feng, Z. *et al.* Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-
targeted therapies. *Biomed. Pharmacother.* **158**, 114174 (2023).

102. Tyebally, R., Xue, A. & Powell, J. E. The potential clinical impact of cell type-specific genetic
regulation: Crohn's disease. *Clin. Transl. Med.* **13**, e1474 (2023).

103. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550
(2005).

104. Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are
coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).

105. CZI Single-Cell Biology Program *et al.* CZ CELL×GENE Discover: A single-cell data platform
for scalable exploration, analysis and modeling of aggregated data. *bioRxiv* (2023)
doi:10.1101/2023.10.30.563174.

1054